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810Objective: Thrombosis occurs in up to 26% of patients with congenital heart disease after cardiac surgery and is
associated with increased morbidity and mortality. Aspirin is commonly administered to reduce the risk of
thrombosis, yet aspirin responsiveness is rarely assessed. In this study, we hypothesize that inadequate response
to aspirin is associated with increased risk of thrombosis after selected congenital cardiac procedures considered
to be high risk for thrombosis.
Methods: Patients undergoing high-risk congenital cardiac surgery who received postoperative aspirin (N¼ 95)
were studied. Response to aspirin was determined using the VerifyNow system several days after administration.
Patients were monitored prospectively for 30 days for the development of a thrombosis event and the relation-
ship between aspirin unresponsiveness and a thrombosis event was determined by the Fisher exact test.
Results: Rate of aspirin unresponsiveness (550 aspirin reaction units [ARU]) was 10 of 95 (10.5%) and was
highest in patients weighing less than 5 kg given 20.25 mg/d of aspirin. Thrombosis events occurred in 7 patients
(7.4%). Thrombosis was observed in 6 of 10 (60%) patients who were unresponsive to aspirin, compared with 1
of 85 (1.2%) patients who were responsive to aspirin (P<.001). In 2 patients who were unresponsive to the
initial aspirin dose, an increase in dose resulted in an adequate therapeutic aspirin response (ARU< 550),
suggesting insufficiency rather than true resistance in a subset of patients.
Conclusions: Postoperative thrombosis is associated with aspirin unresponsiveness in this patient
population. In high-risk patients, monitoring of aspirin therapy and consideration of dose adjustment
or alternative agents for unresponsive patients may be justified and warrants further investigation in a
prospective trial. (J Thorac Cardiovasc Surg 2014;148:810-6)Pediatric patients undergoing cardiac surgery are at higher
risk for thrombosis than the general pediatric population.1,2
Thrombosis rates reported in the literature range from 10%
to 20%; the risk factors for thrombosis include young
age, single ventricle circulation, and duration of central
venous catheters.3-6 Antiplatelet therapy with aspirin is
commonly used to reduce thrombosis after high-risk cardiac
surgical procedures that require either insertion of
prosthetic material or prosthetic valves into the circulation
or significant reconstruction of coronary arteries.
Aspirin resistance has been reported in up to 26% of
pediatric patients with cardiovascular defects undergoing
surgical procedures, and significant interpatient variability
in response to a particular dose of aspirin exists.7 Unpredic-
table aspirin responsiveness in pediatric patients may beoston Children’s Hospital, Boston, Mass.
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resistance. Measurement of platelet inhibition confirms
the efficacy of aspirin, but is rarely performed in this
population. This study tests the hypothesis that significant
interpatient variability in aspirin responsiveness exists
with the current dosing regimen used at our institution.
Furthermore, we hypothesize that, among patients consid-
ered to be at high risk for thrombosis, the rate of thrombosis
events is higher in patients who are unresponsive to aspirin
compared with those who are responsive.METHODS
Patients and Study Design
Pediatric and young adult patients with congenital heart disease
(age<18 years) undergoing cardiac surgery at Boston Children’s Hospital
between January 1, 2013, and May 10, 2014, who were considered to be at
high risk for thrombosis and deemed appropriate for aspirin therapy were
enrolled into a prospective observation study after initiation of aspirin.
Varying doses of aspirin (20.25, 40.5, or 81 mg/d) were administered orally
or via nasogastric tube after postoperative bleeding complications were
stabilized. Patients considered to be at high risk for thrombosis included
those undergoing implantation of prosthetic material into the circulation
(Blalock-Taussig shunt, stage 1 palliation, Fontan procedure, intracardiac
baffles) and those undergoing coronary artery reconstruction (arterial
switch operation, coronary artery unroofing, or reimplantation procedures).
Exclusion criteria included: (1) coadministration of additional antiplatelet
agents (clopidogrel, prasugrel); (2) inability to collect a blood sample;
and (3) documented thrombosis before initiation of aspirin therapy. Thisery c September 2014
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Institutional Review Board and signed consent was obtained.
VerifyNow Aspirin Platelet Function Testing
Aspirin responsiveness was measured using the VerifyNow system
(Accumetrics, San Diego, Calif) for quantitative measurement of platelet
aggregation. This test incorporates activation of platelets in a sample of
whole blood by addition of an agonist, arachidonic acid, and measures
platelet aggregation to fibrinogen-coated beads in a premade testing
cassette. Platelet aggregation leads to increased light transmittance
recorded as aspirin reaction units (ARU). Values less than 550 ARU
indicate aspirin responsiveness; values of 550 ARU or higher indicate
unresponsiveness.
Platelet testing was performed after at least 2 doses of aspirin were
administered to the patients. A sample of whole blood (2 mL) was drawn
into a 3.2% sodium citrate vacuette tube (Greiner Bio-One, Monroe,
NC) by direct venipuncture or from an indwelling catheter after collection
of at least 5 mL of blood, and was incubated for at least 30 minutes (but no
longer than 2 hours) at room temperature according to the manufacturer’s
recommendations. The sample was then loaded into the VerifyNow
cartridge and analyzed by the system.
Assessment of a Thrombosis Event
Patients were followed prospectively to detect the occurrence of a
thrombosis event within 30 days of initiation of aspirin. Weekly review
of clinical records and imaging studies as well as direct interaction with
care providers were used to detect thrombosis events. An echocardiogram
was obtained within 2 weeks after surgery or before discharge in all
patients according to standard clinical care protocol. Clinical thrombosis
events (stroke, shunt thrombosis, limb ischemia) and evidence of throm-
bosis by imaging studies (echocardiography or cardiac catheterization)
were recorded, and the interval to the event was documented. Variables
believed to contribute to the risk of thrombosis (age, concomitant use of
heparin) were also recorded.
Statistical Analysis
Distribution of continuous variables are represented as the median
with the interquartile range (IQR) and comparisons were made using
the independent Student t test. Categorical variables are expressed as
percentages and compared using the Fisher exact test. Multivariate analysis
was used to identify independent predictors of aspirin unresponsiveness
and thrombosis. All statistical tests were 2-tailed.RESULTS
Patient Characteristics
Although 110 patients met the initial inclusion criteria,
only 95 were included in the study because of the inability
to collect blood samples or the occurrence of a thrombosis
event before initiation of aspirin. The general characteris-
tics of the study population are shown in Table 1. Cardiac
surgical procedures performed on patients given aspirin
therapy in the postoperative period are listed in Table 1.
Median time from day of surgery to aspirin administra-
tion was 4 days with an IQR of 3 to 7 days. Aspirin testingThe Journal of Thoracic and Cawas performed at a median of 4 days (IQR, 2-7 days)
after initiation of aspirin. The median dose of aspirin
administered was 6.5 mg/kg/d (IQR, 4.2-9 mg/kg/d).
Although most of the patients received heparin in the
immediate postoperative period, 28 of 95 patients
(29.5%) were on heparin at the time of platelet testing.
Unresponsiveness to aspirin therapy, defined as more than
549 ARU, was present in 10 of 95 (10.5%) patients. The
rate of thrombosis after surgery in this cohort was 7 of 95
(7.4%), and the location of the thrombosis for each patient
is listed in Table 1.
Effect of Aspirin Dose on Unresponsiveness
Aspirin dose administered in this cohort of patients was
20.25, 40.5, or 81 mg/d. The median age, weight and num-
ber of patients categorized by dosage are shown in Table 2.
Of the 7 patients given 20.25 mg/d, 4 (57.1%) were unre-
sponsive to aspirin therapy. All patients in this group were
neonates less than 1 month old and weighed less than
5 kg. For patients receiving 40.5 and 81 mg/d of aspirin,
4 of 50 (8%) and 2 of 38 (5.3%) were unresponsive to
aspirin therapy, respectively. Logistic regression indicated
a significantly higher unresponsiveness rate for 20.25
mg/d versus 40.5 mg/d (57.1% vs 8%; P ¼ .003) and
20.25 mg/d versus 81 mg/d (57.1% vs 5.3%; P ¼ .002)
but no difference between 40.5 mg/d versus 81 mg/d (8%
vs 5.3%; P ¼ .56). In 2 patients who were unresponsive
to an initial aspirin dose of 20.25 and 40.5 mg/d, increasing
the dose to 40.5 and 81 mg/d, respectively, resulted in an
adequate response, suggesting insufficiency rather than
true resistance in this subset of patients.
Relationship Between Aspirin Unresponsiveness and
Thrombosis
Thrombosis was observed in 7 of 95 (7.4%) patients in
this study. Thrombosis developed in 2 of 7 (28.6%) patients
who received 20.5 mg/d, 3 of 50 (6%) patients who
received 40.5 mg/d, and 2 of 38 (5.3%) patients who
were given 81 mg/d (Table 2). Logistic regression indicated
a significantly higher rate of thrombosis for 20.25 mg/d
versus 81 mg/d (28.6% vs 5.3%; P ¼ .025); no significant
differences was observed between 40.5 mg/d versus
81mg/d (6.1% vs 5.3%; P¼ .69). Therewas a trend toward
a difference in the rates of thrombosis between patients
given 20.25 mg/d versus 40.5 mg/d (28.6% vs 6%;
P ¼ .06); this difference was not statistically significant.
Thrombosis occurred more commonly in nonresponders
compared with responders (Figure 1). Only 1 of 85
responders had a thrombosis event after the administration
of aspirin, whereas 6 of 10 nonresponders had a thrombosis
(1.2% vs 60%, respectively; P < .001). Multivariate
logistic regression analysis indicated that, after adjusting
for age (P ¼ .04) and weight (P ¼ .76), aspirin dose was
an independent predictor of unresponsiveness (P < .01)rdiovascular Surgery c Volume 148, Number 3 811
TABLE 1. Patient characteristics
Variable Data
Total number of patients 95
Male, n (%) 55 (57.9)
Age 1.1 y (2.8 mo to 3.1 y)
Weight (kg) 8.15 (4.2-13.9)
Platelet count 31000 cells (per mL) 310 (215-455)
Heparin at time of testing, n (%) 28 (29.5)
Aspirin dose (mg/d) 40.5 (20.25-81)
Aspirin dose (mg/kg/d) 6.5 (4.2-9)
Date of surgery to aspirin administration, d 4 (3-7)
Duration on aspirin before testing, d 4 (2-7)
Thrombosis events, n (%) 7 (7.4)
Surgical procedures, n
Complex valve procedures 27
Fontan 15
Baffle 8
Stage 1 palliation 8
Arterial switch operation 7
Blalock-Taussig shunt 6
Tetralogy of Fallot 5
Bidirectional Glen 6
Coronary artery unroofing 4
TAPVR 3
Extensive branch PA reconstruction 1
Complex LVOT reconstruction 4
ALCAPA coronary artery repair 1
Thrombosis location, n
Multiple locations (Fontan, Baffle and
fenestration, DVT in leg, iliac, femoral
veins, and so forth)
2
Left ventricle 1
Right atrium 1
Shunt thrombosis 1
Stroke 1
Sagittal sinus thrombosis 1
Continuous variables are presented as the median with interquartile range and
categorical variables are expressed as a percentage. TAPVR, Total anomalous
pulmonary venous return; PA, pulmonary artery; LVOT, left ventricular outflow tract;
ALCAPA, anomalous origin of the left coronary artery from the pulmonary artery;
DVT, deep vein thrombosis.
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Dand thrombosis (P< .05). A change in aspirin dose after
aspirin testing occurred in 4 patients. Repeat testing was
performed in only 2 of these patients, demonstrating
conversion from unresponsiveness to adequate response.
In the other 2 patients who did not undergo repeat testing,
the aspirin dose was altered after a thrombosis event.
Among 28 patients receiving heparin at the time of testing,
3 (10.7%) developed thrombosis, and the risk of thrombosis
was not significantly different compared with the entire
cohort.
DISCUSSION
This study demonstrates significant variability in platelet
inhibition after administration of aspirin according to
current practice patterns at a single institution. Our study812 The Journal of Thoracic and Cardiovascular Surgsuggests approximately 10% aspirin unresponsiveness in
the entire cohort, and more than 50% of neonates
undergoing complex cardiac surgical procedures are
unresponsive to an aspirin dosage of 20.25 mg/d. In
pediatric patients undergoing high-risk congenital cardiac
surgical procedures involving insertion of prosthetic
material into the circulation or coronary artery reconstruc-
tion, the thrombosis rate was 7.4% within 30 days of
surgery, and aspirin unresponsiveness was associated with
a higher risk of thrombosis.
This study demonstrates significant variability in response
to a standard dose of aspirin in infants (3-5 mg/kg/d).8
Variability in response to aspirin, particularly in neonates
and infants after cardiac surgery, has been demonstrated
previously.4 These data highlight the importance of
measuring platelet response if therapeutic efficacy is desired.
Unresponsiveness was particularly high (57%) in neonates
who were given 20.25 mg/d (5-10 mg/kg/d). Similarly,
patients greater than 17 years of age and 80 kg body weight
who were given 81 mg/d of aspirin had a relatively high rate
of unresponsiveness (1 in 3). Current practice in our
institution is to administer 81 mg to adolescents, and
unresponsiveness in this group may be related to an aspirin
dose of less than 1 mg/kg/d.
This study was unable to determine whether unrespon-
siveness was related to inadequate dosing or true aspirin
resistance, which implies failure to inhibit platelet func-
tion even at maximal dose. Two infants who were unre-
sponsive at 20.25 and 40.5 mg/d became responsive
after the aspirin dose was increased, suggesting inadequate
dosing as the mechanism of unresponsiveness in a subset
of patients. Previous studies have suggested that the inci-
dence of true aspirin resistance in children is approxi-
mately 2% and that many patients respond to an
appropriate increase in aspirin dosing.4,9 Future studies
should determine if dose adjustment, particularly in
neonates and pediatric patients greater than 80 kg,
improves responsiveness.
The ability of platelet response to aspirin therapy (as a
single agent) to predict thrombotic events has not been
consistently demonstrated in adults, whereas response to
aspirin plus clopidogrel has been shown to predict ischemic
events.4,10-14 There are few reports of data correlating
aspirin responsiveness with thrombosis events in children.
One study on 50 children after cardiac surgery concluded
a lack of correlation.15 One possible reason for the disparate
outcomes compared with our studymay be related to patient
selection; our cohort included patients whowere considered
to be at the highest risk for thrombosis and excluded low-
risk patients from the analysis, whereas the previous study
included even low-risk patients. Another difference may
be the methodology used for detection of thrombosis; in
our study, all patients had echocardiography within 2 weeks
of surgery in addition to clinical assessment, whereas theery c September 2014
TABLE 2. Relationship between aspirin dose and unresponsiveness or thrombosis
Variable 20.25 mg/d 40.5 mg/d 81 mg/d
Number of patients 7 50 38
Age 3 wk (2-4 wk) 5.3 mo (1.7 mo to 1.1 y) 3.25 y (2.4-10.8 y)
Weight (kg) 3 (2.6-3.5) 5.1 (4-7.3) 15.7 (12.3-28.9)
Aspirin unresponsiveness, n (%) 4 (57.1)* 4 (8) 2 (5.3)
Thrombosis, n (%) 2 (28.6)y 3 (6) 2 (5.3)
*Significantly different unresponsiveness to aspirin dose of 20.25 mg/d versus 40.5 mg/d (P ¼ .005) and 20.25 mg/d versus 81 mg/d (P ¼ .003). ySignificantly different rate of
thrombosis to aspirin dose of 20.25 mg/d versus 81 mg/d (P ¼ .025) but not 20.25 mg/d versus 40.5 mg/d (P ¼ .06). Continuous variables are presented as the median with
interquartile range and comparisons were made using the independent Student t test. Categorical variables are expressed as a percentage and compared using the Fisher exact
test.
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assessment of thrombosis events. Given the conflicting
data regarding the relationship between responsiveness
and thrombosis, a larger study will be necessary to confirm
the results of this study.
An association between aspirin unresponsiveness and
thrombosis has several potential clinical implications.
The most important implication is that adjustment of
aspirin dose or the addition of an alternative antiplatelet
or anticoagulant agent may prevent thrombosis in unrespon-
sive patients. However, this hypothesis was not tested in our
study and warrants assessment in a prospective clinical trial.
Although escalation of therapy in unresponsive patients
may reduce the overall rate of thrombosis, it may also
increase the rate of other adverse events, such as bleeding,
Reyes syndrome, gastrointestinal complications, further
emphasizing the importance of a trial to systematically
assess therapeutic impact. The implication that platelet
reactivity testing should be performed routinely after
high-risk cardiac surgery in pediatric populations is based
on demonstration of clinical benefit of testing-based
therapeutic adjustment. Although the definition of unre-
sponsiveness (550 ARU) was extrapolated from adultFIGURE 1. Association between aspirin unresponsiveness and
thrombosis: Circles represent patients with thrombosis and squares
represent patients without thrombosis. Dashed line indicates the cut-off
value for aspirin unresponsiveness (550 aspirin reaction units [ARU]).
*Significant difference in aspirin unresponsiveness between patients with
thrombosis compared with those without thrombosis.
The Journal of Thoracic and Capractice, this value provided a significant discrimination
in clinical behavior in this cohort. Further validation in a
larger trial is necessary to determine the most appropriate
inflection point for pediatric populations. Adjustment of
the threshold value based on clinical data may allow optimi-
zation of the sensitivity and specificity of the test to predict
future thrombosis events.
Our choice of platform for platelet reactivity testing was
based on previous experience and the existing literature. In
recent years, several point-of-care platelet function testing
analyzers have emerged. Currently available systems
include VerifyNow, TEG-5000 Thrombelastograph
(Haemoscope Corporation, Niles, Ill), Multiplate analyzer
(Roche Diagnostics, Indianapolis, Ind), PFA-100 platelet
function assay (Dade Behring, Newark, Del) and
Plateletworks (Helena Laboratories, Beaumont, Tex).16-20
Because of significant variability in the results obtained
from different analyzers, the prevalence of aspirin
unresponsiveness varies widely (5%-51%) between
studies.20 Among these, the VerifyNow analyzer seems to
be the preferred system because it uses arachidonic acid
(a direct activator of cyclooxygenase-1) as the agonist,
whereas others use adenosine diphosphate to assess aspirin
responsiveness.17,19,21
The rate of thrombosis of 7.4% documented in this study
is lower than previously reported.3-5 The lower rate detected
may be attributed to exclusion of patients presenting with
thrombosis before initiation of therapy. Similarly,
although 60% of patients who were unresponsive to
aspirin therapy had a thrombosis event, this number may
not reflect the true incidence of thrombosis in
unresponsive patients. In 2 patients who were found to be
unresponsive on initial testing, the aspirin dose was
increased by the clinical team (who were blinded to the
platelet function results), but repeat testing was not
performed. If these patients who did not have thrombosis
responded to the increased dose of aspirin, then the result
would further bolster the findings of this study.
There are several limitations to this single-center pilot
study. First, the number of patients and thrombosis events
studied is small, limiting its power. Verification in a larger
cohort is necessary to confirm the results. Second, this studyrdiovascular Surgery c Volume 148, Number 3 813
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Dterminated follow-up at 30 days after surgery, but longer-
term follow-up is more relevant, particularly because a
significant proportion of thrombosis-related complications
occur beyond the 30-day time frame. Third, the incidence
of thrombosis may be underestimated by this study because
echocardiography does not detect peripheral vessel
thrombosis.
In conclusion, this study demonstrates that aspirin
unresponsiveness occurs in approximately 10.4% of
patients undergoing specific high-risk congenital cardiac
procedures using the dosing practice of a single institution.
Aspirin unresponsiveness as measured by the VerifyNow
system predicts the 30-day risk of thrombosis in patients
after specific complex cardiac surgical procedures. Future
studies are necessary to demonstrate if monitoring of
aspirin therapy with consequent dose adjustment or addition
of alternative agents for unresponsive patients minimizes
the risk of thrombosis in this cohort.References
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Dr Jennifer Hirsch-Romano (Ann Arbor, Mich). Thank you,
Ram, for an excellent presentation. You really highlight a
significant problem in the congenital heart disease population.
Thromboses in these patients can span from being just challenging
peripheral venous thromboses that make central access incredibly
difficult as these patients age to fatal shunt thrombosis. I think the
understanding of aspirin resistance is really new to our field and we
are just getting new information with studies such as yours. I am
hoping that with a better understanding of aspirin resistance as
well as various antithrombotic agents, we will get a better
understanding of how to manage our patients.
My first question to you is: in all of our neonates, we routinely
use a 40.5-mg dose. I am interested to know whether the high rate
of aspirin unresponsiveness as well as the high thrombosis rate in
your neonates have led to changes in any of the practice
management in your own institution in terms of that dosing.
Dr Emani. A proposed algorithm reflecting the findings of our
study includes the use of a higher dose of 40.5 mg aspirin in
neonates greater than 3 kg. We are hesitant to use 40.5 mg in
patients less than 2.5 kg. But we have started using 40 mg more
commonly in the neonates. The data would support being
more aggressive about testing neonates and then considering a
dose adjustment if unresponsive.
Dr Hirsch-Romano. My next question has to do with the
screening you did within your study. I know you specifically did
echo monitoring for intracardiac thromboses and otherwise fol-
lowed for clinical events. Have you considered doing any routine
screening for peripheral thromboses? Quite often the loss of
venous access in these children is silent without obvious signs of
limb ischemia.
Dr Emani. I think we need to be more thorough in our assess-
ment of peripheral vascular thrombosis, which is under-reported.
In this study, only clinically significant events such as limb
ischemia were used to define peripheral thrombosis. Imaging
studies are suboptimal at detecting asymptomatic events. I thinkery c September 2014
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about imaging and detecting these types of events. Fortunately, the
methodology was consistent among all patients, so although we
may be underestimating the incidence of thrombosis, the relation-
ship of thrombosis to aspirin unresponsiveness still holds true.
Dr Hirsch-Romano. Then my final question has to do with the
use of Plavix. I think the use of Plavix in the pediatric population is
still a bit controversial, but it is certainly increasing at many
congenital heart centers. Are you using Plavix in your pediatric
population; and if so, for what indications?
Dr Emani. Plavix, as you know, also has its downsides. About
20% to 25% of patients are Plavix unresponsive, and the bleeding
risk is higher. But I would certainly use Plavix for a patient who is
at high risk for thrombosis and is resistant to aspirin.
According to our proposed algorithm, in a patient who is unre-
sponsive, if you really want to understand if is this an absorption
issue versus inadequate dosing, you can actually spike the blood
with a maximum dose of aspirin to determine true resistance. I
think in a truly resistant patient I would use Plavix, but would
test for the effect of Plavix as well.
Dr Hirsch-Romano. Can you tell me about your VerifyNow
testing? I know historically when we had a look at various testing
options, quite often they require a fair blood volume, which is chal-
lenging in a neonatal population, or they require a nontourniquet
blood draw, which also can be challenging.
Dr Emani. It requires 2 mL of blood and that is a major issue.
We are working with a couple of different systems, microfluidic
systems, to try to reduce that volume.
A major problem with platelet testing, particularly if you use
small-volume draws, is the hypersensitive nature of the clotting
system after introducing any foreign object into the blood stream.
So a finger stick or a small-volume blood draw is likely to be
contaminated by the contact activation. So novel methods of in
vivo platelet reactivity testing need to be developed to overcome
this limitation.
Dr Henry Walters (Detroit, Mich). This was an excellent pre-
sentation. Jenna, you had mentioned the catastrophic situation in
which there is thrombosis of a systemic-to-pulmonary artery
shunt. If we are still in the mood for surveys, I was wondering if
we could conduct another one.
Dr Carl L. Backer (Chicago, Ill). We are in the mood. Go
ahead.
Dr Walters. Great. Well, I am going to leave the survey
questions up to you, but, for example, after constructing a
systemic-to-pulmonary artery shunt, 1 program might start with
an intravenous heparin infusion and transition to some kind of
antiplatelet agent. Others might use aspirin only, Plavix only, or
a combination. I would be interested in how the members of this
audience approach this situation.
Dr Backer. Dr Hirsch-Romano has already read your mind and
I have got a list here.
For a neonate having a modified Blalock-Taussig shunt (our
biggest fear I think for thrombosis), how many surgeons would
use aspirin only?
(Show of hands.)
It looks like about a third of the hands.
And how many would use Plavix only? Nobody is using
Plavix only.The Journal of Thoracic and CaHow about aspirin plus Plavix?
Nobody. There is no Plavix.
What about heparin, intravenous heparin therapy?
Dr Hirsch-Romano. Heparin bridge to aspirin.
Dr Backer. Heparin bridge to aspirin.
(Show of hands.)
Oh, boy, now everybody’s hands are going up. We have got
about 80% of the audience.
How about Lovenox, injections of Lovenox; who uses
Lovenox?
(Show of hands.)
Only 3 hands for Lovenox.
It seems that most surgeons when they are really concerned
about thrombosis are using heparin followed by aspirin. What
are your thoughts about that Ram?
Dr Emani. I use heparin followed by aspirin, partly because I
do not think there is a great antiplatelet agent for the immediate
postoperative period. When we looked at shunt thrombosis in
particular, it is actually white thrombus suggesting platelet
aggregation rather than thrombosis mediated by the coagulation
system, so an antiplatelet agent is actually what you need.
The question is whether you can do that safely and effectively
with current therapeutic options. But I still use heparin and try
to get it therapeutic before initiation of aspirin.
Dr Sabine Daebritz (Duisburg, Germany). It was an interesting
talk. Did you screen your patients for any other reasons for throm-
bosis like factor V Leiden or heparin-induced thrombocytopenia?
This is important because some of those thromboses, like sagittal
sinus thrombosis, are not considered to be influenced much by
aspirin so they might be caused by something else.
Dr Emani. Yes, many of the patients with thrombosis are
screened for hypercoagulability disorders as well. Some of the
neonates and single-ventricle patients who do not have
thrombosis were screened with a thrombophilia panel as a part
of a separate study. We have found that the presence of a hyperco-
agulability disorder increases the risk of a thrombosis event. The
patient who had sagittal sinus thrombosis particularly did not
have a coagulation abnormality, nor did any of the other patients
who had thrombosis. We did not systematically screen all patients
without thrombosis.
But I would add that even if thrombophilia panels come back
negative, it does not mean that a child does not have some form
of hypercoagulability disorder or platelet hyperreactivity. I would
argue that all high-risk patients should therefore be aggressively
managed with anticoagulation or antiplatelet therapy?
Dr Joseph J. Amato (Chicago, Ill). I was just curious, when
you were doing the diagnosis of atrial septal defect, youmentioned
that a certain percentage, a small percentage, were looked at with
catheterization. Is that a necessity or it just so happened?
Dr Emani. The patients who underwent catheterization for
hemodynamic reasons would have been followed for a thrombosis
event. So we have looked at those images to see if thrombosis
was present as an incidental finding. None of the patients had
thrombosis detected by catheterization alone.
Dr Amato. You could have defined them by just echo alone?
Dr Emani. Right. Most of the catheterizations that occurred
were performed for hemodynamic reasons rather than confirma-
tion of echo.rdiovascular Surgery c Volume 148, Number 3 815
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DDr J.WilliamGaynor (Philadelphia, Pa). Ram, I enjoyed that.
One quick question. There are obviously multiple factors that can
play into the risk of thrombosis, and 1 of those is the shunt itself.
This is completely anecdotally, but a few years ago we switched to
the heparin-bonded shunts and it seems like our rate of thrombosis
(we still use heparin as a bridge to aspirin), but it seems like our
rate of early shunt thrombosis has decreased with that. We have
not looked at it systemically. It is anecdotal. I was wondering
what shunt material you used?
Dr Emani.Well, I was excited when the heparin-bonded shunt
came out and I use that on all of my patients and I have not found a
difference.
The patients who develop thrombosis of polytetrafluoroethy-
lene material demonstrate platelet-mediated occlusion rather
than coagulation-mediated. So I am not sure if the heparin helps816 The Journal of Thoracic and Cardiovascular Surgmuch. As we start to understand the clotting system in general, I
think we can start to understand that there are actually therapies
in each of the systems; the coagulation platelet and fibrinolytic
systems. Hopefully as we collect more data, we can tailor our
approach based on what we think the predominant deficits are.
We need better monitoring systems and better therapeutic options.
Dr Backer. Bill, you bring up a good point. Let me survey the
audience. How many surgeons have switched to using the heparin-
bonded shunts?
(Show of hands.)
And how many are still using the non–heparin-bonded shunts?
(Show of hands.)
Looks like about 50/50 or maybe 60/40 for the heparin-bonded
shunts. Our group has certainly switched to them, and at least
anecdotally I have found that we have had less shunt thrombosis.ery c September 2014
